The WACC of Kinarus Therapeutics Holding AG (KNRS.SW) is 5.0%.
| Range | Selected | |
| Cost of equity | 4.40% - 6.60% | 5.50% |
| Tax rate | 16.80% - 18.00% | 17.40% |
| Cost of debt | 5.00% - 5.00% | 5.00% |
| WACC | 4.3% - 5.7% | 5.0% |
| Category | Low | High |
| Long-term bond rate | 1.3% | 1.8% |
| Equity market risk premium | 5.1% | 6.1% |
| Adjusted beta | 0.61 | 0.7 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 4.40% | 6.60% |
| Tax rate | 16.80% | 18.00% |
| Debt/Equity ratio | 0.54 | 0.54 |
| Cost of debt | 5.00% | 5.00% |
| After-tax WACC | 4.3% | 5.7% |
| Selected WACC | 5.0% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for KNRS.SW:
cost_of_equity (5.50%) = risk_free_rate (1.55%) + equity_risk_premium (5.60%) * adjusted_beta (0.61) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.